5 FDA Decisions for Primary Care to Know from June 2026

In June, the US Food and Drug Administration (FDA) issued several regulatory decisions with potential relevance across primary care, dermatology, infectious disease, and behavioral health. The updates included a first-in-class oral postexposure prophylaxis option for COVID-19, a Complete Response Letter for an investigational ADHD therapy, and clearance of a personalized neuromodulation platform for post-traumatic stress disorder.